Knight Therapeutics Inc.
KHTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $371 | $328 | $294 | $243 |
| % Growth | 13.1% | 11.8% | 20.6% | – |
| Cost of Goods Sold | $197 | $176 | $156 | $128 |
| Gross Profit | $174 | $153 | $138 | $115 |
| % Margin | 47% | 46.5% | 47% | 47.4% |
| R&D Expenses | $23 | $18 | $15 | $13 |
| G&A Expenses | $45 | $37 | $40 | $37 |
| SG&A Expenses | $99 | $84 | $89 | $74 |
| Sales & Mktg Exp. | $54 | $46 | $48 | $37 |
| Other Operating Expenses | $44 | $54 | $52 | $41 |
| Operating Expenses | $167 | $156 | $155 | $128 |
| Operating Income | $7 | -$3 | -$2 | -$5 |
| % Margin | 2% | -0.9% | -0.8% | -2.2% |
| Other Income/Exp. Net | -$5 | -$19 | -$3 | $20 |
| Pre-Tax Income | $2 | -$22 | -$44 | $7 |
| Tax Expense | -$2 | -$5 | -$14 | -$9 |
| Net Income | $4 | -$17 | -$30 | $16 |
| % Margin | 1.2% | -5.1% | -10.2% | 6.4% |
| EPS | 0.045 | -0.16 | -0.26 | 0.13 |
| % Growth | 127.9% | 38.5% | -300% | – |
| EPS Diluted | 0.043 | -0.16 | -0.26 | 0.13 |
| Weighted Avg Shares Out | 97 | 107 | 115 | 124 |
| Weighted Avg Shares Out Dil | 101 | 107 | 115 | 125 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $13 | $11 | $7 |
| Interest Expense | $9 | $12 | $7 | $4 |
| Depreciation & Amortization | $53 | $50 | $63 | $48 |
| EBITDA | $64 | $41 | $25 | $43 |
| % Margin | 17.3% | 12.5% | 8.6% | 17.5% |